---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-21-000024"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2021-10-27T23:59:59+00:00"
generated_at: "2026-06-28T17:16:26.309283+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences Q3 sales up 15% to $1.3B; EPS $0.54; guidance reaffirmed

## Summary
- Q3 sales $1.3B, up 15% reported (14% underlying); TAVR sales $858M, up 15% (14% underlying).
- Adjusted EPS $0.54; full-year 2021 sales guidance unchanged at $5.2-$5.4B; adjusted EPS guided to high end of $2.07-$2.27.
- TMTT sales $22M; company on track for U.S. approval of PASCAL platform for degenerative mitral regurgitation late 2022.
- Free cash flow $471M in Q3, $1.1B YTD; cash and investments $3.1B, total debt $596M.
- Q4 2021 guidance: sales $1.30-$1.38B, TAVR $850-$910M, adjusted EPS $0.53-$0.59.

## SEC filing metadata
- accession: 0001099800-21-000024
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2021-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/0001099800-21-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980021000024/ew-20211027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-21-000024
- JSON: https://secwatch.observer/filing/0001099800-21-000024.json
- Plain text: https://secwatch.observer/filing/0001099800-21-000024.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.